B-lymphocyte contributions to human autoimmune disease.

TitleB-lymphocyte contributions to human autoimmune disease.
Publication TypeJournal Article
Year of Publication2008
AuthorsYanaba K, Bouaziz J-D, Matsushita T, Magro CM, E St Clair W, Tedder TF
JournalImmunol Rev
Volume223
Pagination284-99
Date Published2008 Jun
ISSN1600-065X
KeywordsAnimals, Antibodies, Monoclonal, Antibodies, Monoclonal, Murine-Derived, Antigen Presentation, Autoimmune Diseases, B-Lymphocytes, CD4-Positive T-Lymphocytes, Humans, Immunologic Memory, Immunotherapy, Interleukin-10, Lymphocyte Activation, Lymphocyte Depletion, Mice, Rituximab
Abstract

SUMMARY: Autoimmunity results from abnormal B- and T-cell recognition of self-antigens, which leads to autoantibody production in many cases. Autoantibodies produced by B-cell-derived plasma cells provide diagnostic markers for autoimmunity but also contribute significantly to disease pathogenesis. As discussed in this review, the therapeutic benefit of depleting B cells in mice and humans has refocused attention on B cells and their role in autoimmunity beyond autoantibody production. B cells specifically serve as cellular adjuvants for CD4(+) T-cell activation, while regulatory B cells, including those that produce interleukin-10 (B10 cells), function as negative regulators of inflammatory immune responses. The emerging picture is that B cells, autoantibodies, and T cells are all important components of abnormal immune responses that lead to tissue pathology unique to each autoimmune disease, with their relative contributions changing during disease progression. Autoimmune diseases where B-cell functions are closely correlated with disease activity include systemic lupus erythematosus, rheumatoid arthritis, scleroderma, type 1 diabetes, and multiple sclerosis. Understanding the overlapping roles of B cells as mediators of autoimmune disease will facilitate the development of more precisely directed therapies and combination therapies with broader clinical efficacy than current depletion strategies that remove all B cells.

DOI10.1111/j.1600-065X.2008.00646.x
Alternate JournalImmunol Rev
PubMed ID18613843
Grant ListAI56363 / AI / NIAID NIH HHS / United States
CA96547 / CA / NCI NIH HHS / United States
CA105001 / CA / NCI NIH HHS / United States
Related Faculty: 
Cynthia M. Magro, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700